Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Paul Hallenbeck
AddedMar 31, 2024
UpdatedMay 31, 2026
Paul Hallenbeck

Paul Hallenbeck

Founder & CEO, Synbody Biotechnology

CrunchbaseLinkedIn

Paul Hallenbeck's Career

Synbody Biotechnology
Synbody Biotechnology

Farmington, CT, US

Founder & CEO· C-Suite · Management
Seneca Therapeutics
Seneca Therapeutics

Blue Bell, PA, US

Founder
Neotropix
Neotropix

Malvern, PA, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Paul Hallenbeck's Career

Synbody Biotechnology
Synbody Biotechnology
Public$750k52010Farmington, CT, US
Founder & CEO· C-Suite · Management

Leadership at Synbody Biotechnology

Daniel WagnerDaniel WagnerBoard Member

Similar to Synbody Biotechnology

RbioRbioSan Francisco, CA, USPharmaceuticalsest. 2020RbioSan Francisco, CA, US · est. 2020

Synthetic Biology-based Pharmaceutical Manufacturing Company

Pre-Seed · $60k3
Zebra BiologicsZebra BiologicsConcord, MA, USAntibody Therapeuticsest. 2013Zebra BiologicsConcord, MA, US · est. 2013

US-based Zebra Biologics, Inc. pioneers in discovering and developing advanced antibody therapeutics since 2013.

Seed · $12M8
SynlifeSynlifeCambridge, MA, USMedical Researchest. 2017SynlifeCambridge, MA, US · est. 2017

Synlife: Innovating therapeutic and diagnostic solutions through engineered synthetic cells for medical research.

Seed · $700k2
iBioiBioNew York City, NY, USAntibody Therapeuticsest. 2008iBioNew York City, NY, US · est. 2008

iBio, Inc.: A US-based biopharmaceutical company specializing in plant-made products for treating serious infectious diseases.

Public · $38.1M26
Seneca Therapeutics
Seneca Therapeutics
Series A$7.7M72018Blue Bell, PA, US
Founder

Leadership at Seneca Therapeutics

James HusseyJames HusseyCEO

Similar to Seneca Therapeutics

PineTree TherapeuticsPineTree TherapeuticsCambridge, MA, USBiotech Therapiesest. 2019PineTree TherapeuticsCambridge, MA, US · est. 2019

PineTree Therapeutics: Innovating biotech therapies in Oncology and Immuno-oncology.

Series B · $23.5M17
Palm TherapeuticsPalm TherapeuticsSan Diego, CA, USCancer Treatmentest. 2018Palm TherapeuticsSan Diego, CA, US · est. 2018

Revolutionizing cancer treatment with next-gen root-level therapeutics.

Angel · $991.1k7
Mana TherapeuticsMana TherapeuticsArlington, VA, USCancer Treatmentest. 2018Mana TherapeuticsArlington, VA, US · est. 2018

Passionate team harnessing immune cells to combat and confer lifelong immunity to cancer.

Series A · $49.5M7
Checkpoint TherapeuticsCheckpoint TherapeuticsWaltham, MA, USCancer Therapiesest. 2014Checkpoint TherapeuticsWaltham, MA, US · est. 2014

Checkpoint Therapeutics: A clinical-stage biopharmaceutical company focused on cancer therapy development.

Public · $10M24
Neotropix
Neotropix
Acquired$11.4M02003Malvern, PA, US
Founder

Leadership at Neotropix

Matt RiekeMatt RiekeBoard Member
Peter LancianoPeter LancianoBoard Member
Sena BiswasSena BiswasBoard Member
Chris KroegerChris KroegerBoard Member

Similar to Neotropix

DnatrixDnatrixHouston, TX, USOncolytic Virus Therapiesest. 2005DnatrixHouston, TX, US · est. 2005

DNAtriX, a Houston-based biotech firm, develops oncolytic virus platforms to treat malignant glioma.

Series B · $57.1M33
IconOVir BioIconOVir BioSan Diego, CA, USOncolytic Virusest. 2018IconOVir BioSan Diego, CA, US · est. 2018

IconOVir Bio: A preclinical biotech firm innovating personalized oncolytic virus cancer therapies.

Series A · $77M8
NeoantigenicsNeoantigenicsCharlottesville, VA, USCancer Therapiesest. 2012NeoantigenicsCharlottesville, VA, US · est. 2012

Neoantigenics: Pioneering oncology theranostics for urogenital and solid cancers since 2012.

Seed · $2.5M30
Neonc TechnologiesNeonc TechnologiesLos Angeles, CA, USCancer Treatmentest. 2008Neonc TechnologiesLos Angeles, CA, US · est. 2008

NEONC Technologies: An early-stage biotech firm innovating in cancer treatment through unique delivery of plant-derived agents.

Series A · $10.2M6

Paul Hallenbeck's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · Kakao

People Similar to Paul Hallenbeck

Joseph VitaleJoseph VitaleBoard Member · Seneca SavingsDan PiacquadioDan PiacquadioFounder · TherapeuticsRick PierceRick PierceFounder & CEO · SanaRx BiotherapeuticsJohn BoyceJohn BoyceFounder · TigerGenePatrick RitschelPatrick RitschelCEO · Atsena TherapeuticsRay LiRay LiCEO · Sene